These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 30377572)

  • 21. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.
    Nishii N; Tachinami H; Kondo Y; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Harada H; Azuma M
    Oncotarget; 2018 Mar; 9(17):13301-13312. PubMed ID: 29568358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia.
    Msika A; Mathias V; Boudigou M; Chambon M; Dubois V; Hajri T; Lotz JP; Massardier J; Descargues P; Gladieff L; Joly F; Lebreton C; Maucort-Boulch D; Bin S; Rousset P; Allias F; Gaillot-Durand L; Devouassoux-Shisheboran M; Lemaitre N; Alfaidy N; Langlois-Jacques C; Alves-Ferreira M; Golfier F; You B; Thaunat O; Bolze PA; Koenig A
    Am J Obstet Gynecol; 2024 Oct; ():. PubMed ID: 39370035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 24. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model.
    Abdolahi S; Ghazvinian Z; Muhammadnejad S; Ahmadvand M; Aghdaei HA; Ebrahimi-Barough S; Ai J; Zali MR; Verdi J; Baghaei K
    Front Pharmacol; 2021; 12():733075. PubMed ID: 34588986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 27. CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade.
    Zheng A; Du Y; Wang Y; Zheng Y; Ning Z; Wu M; Zhang C; Zhang D; Liu J; Liu X
    Mol Ther Nucleic Acids; 2022 Mar; 27():998-1009. PubMed ID: 35228895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
    Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
    Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
    Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
    Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
    Ahmad G; Mackenzie GG; Egan J; Amiji MM
    Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.
    Oyer JL; Pandey V; Igarashi RY; Somanchi SS; Zakari A; Solh M; Lee DA; Altomare DA; Copik AJ
    Cytotherapy; 2016 May; 18(5):653-63. PubMed ID: 27059202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
    Kang SH; Keam B; Ahn YO; Park HR; Kim M; Kim TM; Kim DW; Heo DS
    Oncoimmunology; 2019; 8(1):e1515057. PubMed ID: 30546955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a
    Takeda Y; Azuma M; Funami K; Shime H; Matsumoto M; Seya T
    Front Immunol; 2018; 9():496. PubMed ID: 29593736
    [No Abstract]   [Full Text] [Related]  

  • 35. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
    Knudson KM; Hicks KC; Luo X; Chen JQ; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(5):e1426519. PubMed ID: 29721396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.
    Zha H; Han X; Zhu Y; Yang F; Li Y; Li Q; Guo B; Zhu B
    Oncoimmunology; 2017; 6(10):e1349587. PubMed ID: 29123963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of
    Baraibar I; Roman M; Rodríguez-Remírez M; López I; Vilalta A; Guruceaga E; Ecay M; Collantes M; Lozano T; Alignani D; Puyalto A; Oliver A; Ortiz-Espinosa S; Moreno H; Torregrosa M; Rolfo C; Caglevic C; García-Ros D; Villalba-Esparza M; De Andrea C; Vicent S; Pío R; Lasarte JJ; Calvo A; Ajona D; Gil-Bazo I
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33126649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.